Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Galectin Therapeutics Inc
GALTCurrent price
1.65 USD
-0.01 USD (-0.60%)
Last closed
1.59 USD
Company
galectintherapeutics.com
ISIN
US3632252025
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
144 979 760 USD
Yield for 12 month
-29.18 %
1Y
3Y
5Y
10Y
15Y
GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Address: 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-33 000 USD
Last Year
-32 000 USD
Current Quarter
–
Last Quarter
-9 000 USD
Key Figures GALT
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-103.87 %
PEG Ratio
–
Return On Equity TTM
-3 727.95 %
Wall Street Target Price
11.00 USD
Revenue TTM
–
Book Value
-1.01 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.73 USD
Diluted Eps TTM
-0.73 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics GALT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History GALT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
23.03.2012
Stock Valuation GALT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-4.04
Price Book MRQ
207.70
Financials GALT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators GALT
For 52 weeks
1.56 USD
4.27 USD
50 Day MA
2.59 USD
Shares Short Prior Month
5 702 047
200 Day MA
2.65 USD
Short Ratio
42.37
Shares Short
5 857 911
Short Percent
18.41 %
BeatStart